Trombocitopenia grave inducida por levofloxacino

Arroyo, L. Álvarez; Gil, M. Perdiguero; Grana, Eduardo Climent; Baines, Juan Pablo Ordovás

doi:10.1016/s1130-6343(07)75383-7

Cited by 9 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fluoroquinolones (FQ) are among the most important group of drugs for the treatment of MDR-TB. Few cases of hematologic reaction due to levofloxacin were reported [ 73 ]. Thrombocytopenia, pancytopenia, microangiopathy and hemolytic anemia are adverse events related to levofloxacin administration [ 73 , 74 , 75 ].…”

Section: Hematologic Adverse Event Associated With Tb Treatmentmentioning

confidence: 99%

Common and Rare Hematological Manifestations and Adverse Drug Events during Treatment of Active TB: A State of Art

et al. 2021

View full text Add to dashboard Cite

Background: Tuberculosis (TB) can seriously affect the hematopoietic system, with involvement of both myeloid and lymphoid cell lines as well as plasma components. These hematological changes act as a marker for the diagnosis, prognosis and response to therapy. Methods: We searched PubMed, Scopus, Google Scholar, EMBASE, Cochrane Library and WHO websites from 1950 to May 2021 for papers on the interaction between TB and common and rare hematological manifestation. Results: Hematological reactions in patients with TB are possible in both young and old women and men but seem more frequent in the elderly, and they can be predictors of both diagnosis and worse outcome for TB, regardless of whether it is pulmonary, extra pulmonary or miliary. Even anti-TB therapies can cause hematological adverse events, among which some are serious and rare and can compromise the patient’s recovery pathway to completing treatment. Conclusion: Hematological screening and follow-up, including complete blood count and coagulation, are always necessary both at the diagnosis of TB and during antitubercular treatment in order to monitor hematological parameters. Short therapy regimens for multidrug-resistant TB (MDR-TB) may also be useful for reducing hematological toxicity, especially in contexts where this cannot be monitored. Close monitoring of drug interactions and hematological adverse events is always recommended.

show abstract

Section: Hematologic Adverse Event Associated With Tb Treatmentmentioning

confidence: 99%